September 2, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma. more info >>
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
(Apr 14, 2014)
Kaneka Corporation and RIKEN have successfully biosynthesized polyhydroxyalkanoic acid (PHA), a type of bioplastic, generated by microorganisms using degradation products of lignin, a plentiful component found in wood, as a carbon source. more info >>
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Takara Bio Inc. announced that as of April 4 it had completed enrollment of a Phase I clinical trial of HF10 in patients with solid tumors in the US; 28 patients enrolled and 22 patients evaluable. more info >>
ACN Newswire
 Press Release News

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)
Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). more info >>
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. more info >>
Eisai Supports Earthquake Relief Efforts in Yunnan, China (Aug 7, 2014)
Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China. more info >>
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment (July 31, 2014)
Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate in the treatment of radioiodine-refractory differentiated thyroid cancer. more info >>
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy (July 3, 2014)
Eisai Co., Ltd. announced today that it has received approval from the European Commission of the indication expansion of Halaven to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. more info >>
 Global Press Release

Understanding and Improving the Body's Fight Against Pathogens (Sept 1, 2014)

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)

Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy (Aug 20, 2014)

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)

Carbon Nanotubes and Near-infrared Lasers Promise a Cost Effective Solution for Cell Membrane Manipulation (Aug 15, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)